Vice President, Integrated Product Medical Lead

Bayer•Cambridge, MA

About The Position

At Bayer we’re visionaries, driven to solve the world’s toughest challenges and striving for a world where 'Health for all Hunger for none’ is no longer a dream, but a real possibility. We’re doing it with energy, curiosity and sheer dedication, always learning from unique perspectives of those around us, expanding our thinking, growing our capabilities and redefining ‘impossible’. There are so many reasons to join us. If you’re hungry to build a varied and meaningful career in a community of brilliant and diverse minds to make a real difference, there’s only one choice. Vice President, Integrated Product Medical Lead The Integrated Product Medical Lead (IPML) is a key figure for advancing the oncology early development portfolio. You will create significant impact through the successful progression of global development programs and the expansion of our pipeline.The IPML sets the vision and strategic direction of assigned programs and is responsible for a medically and clinically sound end-to-end development strategy for our products across various modalities, biologies and indications, representing the full value chain from pre-D1 up to hand-over to late-stage drug development (following Proof-of-Concept and the decision to enter pivotal studies). The IPML builds an end-to-end clinical strategy and is responsible for the successful execution of development programs on behalf of Early Clinical Development Oncology, providing clinical-scientific leadership for one or more global development programs with full decision-making authority in his/her sphere of influence. Together with cross-functional IPT members, the IPML drives the creation and maintenance of a target product and target value profile to maximize the clinical success of development programs and therefore significantly shapes the value of the product. Already during the pre-clinical stages within development, the IPML is responsible for driving value and differentiation of ONC assets based on the scientific hypothesis of a molecule as well as the current and future standard of care in the relevant therapeutic area. Furthermore, the IPML co-leads the successful incorporation of novel assets into the pipeline through supporting internal (e.g., target identification) and external innovation (e.g., due diligences) efforts. In addition, every IPML is accountable for significantly shaping functional excellence within Early Clinical Development Oncology by driving core project, people, and innovative clinical development topics under a peer-reviewed setting, as well as pushing the boundaries of drug development in close collaboration with internal and external researchers. In addition, every IPML is accountable for significantly shaping functional excellence within ECDO by driving core project, people, and innovative clinical development topics under a peer-reviewed setting, as well as pushing the boundaries of drug development in close collaboration with internal and external researchers

Requirements

M.D. with board certification within oncology/hematology or associated subspecialties
Scientific excellence: Demonstrated by a track record of relevant basic and/or translational research documented in peer reviewed publications
Outstanding drug development expertise:
Knowledge of the whole R&D process and the key drivers for success as well as strong understanding of the elements of drug development programs
Experience in different drug development stages
Has the ability to independently develop a sound (medical) strategy and may teach others to do so
Expertise across different biologies and modalities including small and large molecules
Relevant global health authority interactions and current knowledge of regulatory review and responses
Exposure to and understanding of commercial considerations in relation to drug development
Sets the right priorities, seizes strategic opportunities, and adheres to high standards
Shows excellent communication and leadership skills, coupled with strategic thinking as well as good business and external trends insights
Focuses on outcomes - defines and proactively delivers on high pipeline, team, talent and organizational impact outcomes
Acts, learns fast and evolves: works in 90-days cycles, applies learnings and continually develops
Co-creates for customers: remains close to the customer - develops and co-creates solutions for their needs
High energy with focus and vision; self-motivated with a high sense of ownership, urgency, proactive and solution-oriented, flexible entrepreneurial and open-minded approach to new and creative ideas.

Nice To Haves

5+ years of drug development experience with at least 2+ years of expertise in early drug development
5+ years in direct patient care and board certification within oncology/hematology or associated subspecialties.

Responsibilities

Acts as the clinical leader and primary clinical representative for the global program(s) assigned to him/her and represents them both, internally and externally facing. As such, the IPML ensures consistent high quality and speed of functional deliverables to drive sustained value creation for patients and the business and ensures an “end-to-end” clinical vision and strategy for the respective asset is defined. The IPML pushes the boundaries of early drug development to accelerate and improve decision making, while continuously implementing the patient’s perspective and always ensuring patient’s safety and benefit;
In preparation for assets entering the portfolio, the IPML develops a clinical vision if and how a molecule can address an unmet medical need considering the molecule’s scientific hypothesis and the current and future treatment landscape. Based on this vision, the IPML designs a clinical strategy to guide preclinical and clinical development enabling early and definitive decision-making. In line with the strategy, the IPML plans and executes clinical trials focusing on patient centricity, urgency and speed ensuring patients benefit at any point in time during trial conduct and enabling the collection of all relevant information for further seamless clinical development. The IPML is responsible for study medical/safety aspects and risk-benefit assessments supported by Pharmacovigilance and Clinical Science;
Is accountable for the timely delivery of milestones, mitigates roadblocks and is empowered to take decisions to effectively execute on the clinical strategy;
Supports the preclinical evaluation and validation of new oncology assets in line with the overarching RED ONC strategy focusing on value, differentiation, and unmet medical need (e.g., through interacting with BD&L, LEAPS, Collaboration to Cure Hubs, CoLab incubator);
In alignment with the overall ECDO and RED-ONC strategy, identifies new opportunities for collaboration and manages excellent relationships with new and existing partners, both within as well as outside of Bayer, to drive clinical excellence;
Can lead and drive ECDO-initiated (cross-)functional strategic initiatives in support of the overall ECDO, RED-ONC, Oncology and/or Bayer strategy; can act as a representative of ECDO in other cross-functional activities and workstreams where required. When required, can deputize for the Head of ECDO and act as ECDO representative in Bayer internal governance bodies;
Independently leads self-empowered matrix teams in-line with Bayer’s VACC leadership standards by enabling, empowering, and supporting colleagues in a high-performance environment under a culture of psychological safety. As such, the IPML takes accountability for the respective team outcomes and promotes a creative and innovation-friendly collaboration between clinicians and scientists;
Takes accountability for the respective team outcomes and promotes a creative and innovation-friendly collaboration between clinicians and scientists;
Takes ownership for the entire ECDO team, fosters a culture of ownership in support of the strategy and in line with Bayer’s values; empowers others and drives peer accountability across portfolio deliverables and beyond;
Evolves ECDO’s unique value contribution and thereby drives the development of a productive and fulfilled workforce by embracing a culture of creativity and innovation, while ensuring that capabilities are available and actively evolving accountability across portfolio deliverables and beyond.